Table 3 Best objective response by RECIST 1.1 in patients who received AZD7648 monotherapy or AZD7648 in combination with PLD.

Best objective response, n (%)	AZD7648 5 mg QD (n = 1)	AZD7648 5 mg BID (n = 1)	AZD7648 10 mg BID (n = 1)	AZD7648 20 mg BID (n = 1)	AZD7648 40 mg BID (n = 2)	AZD7648 80 mg BID (n = 4)	AZD7648 160 mg BID (n = 2)	All (n = 12)
Complete response*	0	0	0	0	0	0	0	0
Partial response*	0	0	0	0	0	0	0	0
Stable disease^†	1 (100.0)	0	1 (100.0)	0	0	1 (25.0)	1 (50.0)	4 (33.3)
Disease progression	0	1 (100.0)	0	1 (100.0)	1 (50.0)	1 (25.0)	1 (50.0)	5 (41.7)
Death	0	0	0	0	1 (50.0)	1 (25.0)	0	2 (16.7)
Not evaluable^‡	0	0	0	0	0	1 (25.0)	0	1 (8.3)
Best objective response, n (%)	AZD7648 20 mg BID + PLD 40 mg/m² (n = 2)	AZD7648 20 mg QD 7 days + PLD 40 mg/m² (n = 2)		AZD7648 20 mg QD 7 days + PLD 40 mg/m² (n = 5)		AZD7648 30 mg QD 7 days + PLD 40 mg/m² (n = 6)		All (n = 15)
Complete response*	0	0		0		0		0
Partial response*	0	1 (50.0)		0		0		1 (6.7)
Stable disease^†	1 (50.0)	1 (50.0)		0		2 (33.3)		4 (26.7)
Disease progression	0	0		4 (80.0)		2 (33.3)		7 (46.7)
Death	0	0		0		1 (16.7)		1 (6.7)
Not evaluable^‡	1 (50.0)	0		1 (20.0)		1 (16.7)		3 (20.0)

BID twice daily, QD once daily, PLD pegylated liposomal doxorubicin, RECIST Response Evaluation Criteria in Solid Tumours. RECIST version 1.1.
*Response required confirmation after 4 weeks.
^†All patients with a best objective response of stable disease had stable disease duration of ≥8 weeks.
^‡Patients who were not evaluable had incomplete post-baseline assessment.

Quick links

Search